2. Results
±
REGRESSION
The flowchart illustrating the study design is shown in The characteristics of the participants are listed in After 12 months, the active group showed a statistically significant reduction in DPD levels from baseline (To assess the efficacy of treatment, we calculated the percentage difference between the initial and final values. The percentage changes in all bone metabolism markers and BMD were significantly different between the placebo and active groups: DPD −32.63 ± 12.08%, To confirm these findings and determine the best predictive factor for percentage changes in BMD, multivariable linear regression analysis was conducted (The fitted regression model was 0.495 + 0.216 × (% change in BAP) − 0.014 × (% change in OC) + 0.008 × (% change in TRACP-5b) + 0.052 × (% change in DPD) + 3.394 × (active group). The overall regression was statistically significant (rTo better define the role of treatment in improving BMD, a linear regression analysis was performed by group. The analysis tested whether the percentage changes in OC, BAP, DPD, and TRPC-5b significantly predicted the percentage changes in BMD within each group. In the placebo group, no predictors of changes in BMD were identified. However, in the intervention group, a statistically significant association was observed between percentage changes in BAP and percentage changes in BMD (